Navigating Executive Orders and DOJ Memos That Threaten Criminal Prosecution
FDA Law Blog: Biosimilars
MAY 26, 2025
Were not trying to bury the lead here, but the battle of labeling these surgical and drug treatments is a political one. And the memo goes one step more arguing that, even if otherwise truthful, promotion of off-label uses of hormones can run afoul of FDA prohibitions on misbranding and mislabeling. See United States v. Facteau , 89 F.4th
59 
Let's personalize your content